Skip to Main Content

Paper Details

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Curr Med Res Opin
10
2013

Datasets

Release 1.2